Logo

Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer

Share this
Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer

M&A

Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer

Phase III POLO trial met its primary endpoint of progression-free survival

AstraZeneca and MSD?s Lynparza is the first PARP inhibitor to demonstrate benefit in gBRCAm metastatic pancreatic cancer in a Phase III trial

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III POLO trial. Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with?Lynparza?(olaparib) vs. placebo. The safety and tolerability profile of?Lynparza?was consistent with previous trials. POLO is a randomised, double-blinded, placebo-controlled trial exploring the efficacy of?Lynparza?tablets as 1st-line maintenance monotherapy in patients with germline?BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease has not progressed on platinum-based chemotherapy. Jose? Baselga, Executive Vice President, Research and Development, Oncology, said: ?This is the first positive Phase III trial of any PARP inhibitor in germline?BRCA-mutated metastatic pancreatic cancer, a devastating disease with critical unmet need. The results of POLO provide further evidence of the clinical benefit of?Lynparza?across a variety of?BRCA-mutated tumour types. We will discuss these results with global health authorities as soon as possible.? Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, MSD Research Laboratories, said: ?Trials like POLO demonstrate the shared commitment of MSD and AstraZeneca to assess treatments for difficult-to-treat cancers. The clinically-meaningful results of this trial potentially support the value of testing for germline?BRCA?mutations in patients with metastatic pancreatic cancer.? AstraZeneca and MSD plan to present the full data from the trial at a forthcoming medical meeting. About POLO POLO is a Phase III randomised, double-blinded, placebo-controlled, multicentre trial of?Lynparza?tablets (300mg twice daily) as maintenance monotherapy vs. placebo. The trial randomised 154 patients with gBRCAm metastatic pancreatic cancer whose disease had not progressed on 1st-line platinum-based chemotherapy. Patients were randomised (3:2) to receive?Lynparza?or placebo until disease progression. The primary endpoint was PFS and key secondary endpoints included overall survival, time to second disease progression, overall response rate, disease control rate and health-related quality of life. About?Lynparza Lynparza?(olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response in cells/tumours harbouring a deficiency in homologous recombination repair (HRR), such as mutations in?BRCA1 and/or?BRCA2. Inhibition of PARP with?Lynparza?leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.?Lynparza?is being tested in a range of PARP-dependent tumour types with defects and dependencies in the DDR. Lynparza, which is being jointly developed and commercialised by AstraZeneca and MSD, is approved for multiple indications in advanced ovarian cancer and metastatic breast cancer and has been used in over 20,000 patients worldwide.?Lynparza?has the broadest and most advanced clinical trial development programme of any PARP inhibitor, and AstraZeneca and MSD are working together to understand how it may affect multiple PARP-dependent tumours as a monotherapy and in combination across multiple cancer types.?Lynparza?is the foundation of AstraZeneca?s industry-leading portfolio of potential new medicines targeting DDR mechanisms in cancer cells. About pancreatic cancer Pancreatic cancer is the 12th most common cancer worldwide,1?with 466,000 new cases in 2018 alone.1?Germline?BRCA-mutated pancreatic cancer accounts for five to seven percent of all cases globally.2?With the worst survival rate of the most common cancers,3?it is the 4th leading cause of cancer death,4?and less than seven percent of patients survive more than five years after diagnosis.3?Early diagnosis of pancreatic cancer is difficult, as often there are no symptoms until it is too late.5?Around 80% of patients are diagnosed at the metastatic stage.6 About?BRCA?mutations BRCA1 and?BRCA2 are human genes that produce proteins responsible for repairing damaged DNA and play an important role in maintaining the genetic stability of cells. When either of these genes is mutated, or altered, such that its protein product either is not made or does not function correctly, DNA damage may not be repaired properly, and cells become unstable. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer. About the AstraZeneca and MSD strategic oncology collaboration In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US, known as MSD outside the United States and Canada, announced a global strategic oncology collaboration to co-develop and co-commercialise?Lynparza, the world?s first PARP inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for multiple cancer types. Working together, the companies will develop?Lynparza?and selumetinib in combination with other potential new medicines and as monotherapies. Independently, the companies will develop?Lynparza?and selumetinib in combination with their respective PD-L1 and PD-1 medicines. About AstraZeneca in Oncology AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients? lives and the Company?s future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance Oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology. By harnessing the power of four scientific platforms ? Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates ? and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit?astrazeneca.com?and follow us on Twitter?@AstraZeneca.

Share this article on WhatsApp, LinkedIn and Twitter



Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions